Pacira Biosciences Inc Stock Price, News & Analysis

Pacira BioSciences (NASDAQ: PCRX) announced promising three-year clinical data for PCRX-201, their investigational gene therapy for knee osteoarthritis. The Phase 1 trial involving 72 patients demonstrated that a single intra-articular injection of PCRX-201 provided sustained improvements in pain, stiffness, and function through 156 weeks. Key results from the corticosteroid-pretreated cohort showed 51-53% reduction in pain scores, 38-76% reduction in stiffness scores, and 26-28-point improvements in daily living function scores. The therapy was well-tolerated with no serious treatment-related adverse events. PCRX-201, which received FDA's RMAT designation in March 2024 and EMA's ATMP designation in May 2023, works by targeting chronic inflammation at the cellular level through its proprietary HCAd gene therapy vector platform. The company is currently conducting Phase 2 trials following these encouraging results.

Pacira BioSciences (PCRX) has granted inducement awards to 19 new employees on June 3, 2025, under its Amended and Restated 2014 Inducement Plan. The awards include stock options for 11 employees to purchase 26,700 shares and restricted stock units (RSUs) for 19 employees covering 41,600 shares. The stock options have a 10-year term with a four-year vesting schedule, starting at 25% after the first year and quarterly installments thereafter. The exercise price is set at $26.40 per share. The RSUs vest annually in four equal installments beginning June 1, 2026. All awards are contingent on continued employment and were approved by the People & Compensation Committee without stockholder approval.

Pacira BioSciences (NASDAQ: PCRX) has presented promising preliminary data for its gene therapy candidate PCRX-201 in treating knee osteoarthritis. The Phase 1 trial involving 72 participants demonstrated that pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the therapy's safety or effectiveness. The study showed that PCRX-201, which uses a proprietary high-capacity adenovirus vector platform, improved pain, stiffness, and function across all tested doses. Notably, corticosteroid pretreatment helped reduce treatment-induced antibody titers and joint swelling. The therapy received RMAT designation from the FDA in March 2024 and ATMP designation from the EMA in May 2023. A Phase 2 study (ASCEND) is currently underway, targeting the 14 million patients suffering from knee osteoarthritis.

Pacira BioSciences (NASDAQ: PCRX), a leader in non-opioid pain therapies, has announced its participation in two upcoming healthcare conferences. The company will engage in analyst-led fireside chats at:

- The 2025 RBC Capital Markets Global Healthcare Conference on May 21st at 8:30 AM ET

- The 2025 Jefferies Global Healthcare Conference on June 4th at 8:45 AM ET

Both events will be accessible via live audio webcast through the "Events" page on Pacira's investor website. Recordings will remain available for two weeks after each event.

Pacira BioSciences (PCRX) reported Q1 2025 financial results with total revenues of $168.9 million. Key product sales included EXPAREL at $136.5 million, ZILRETTA at $23.3 million, and iovera° at $5.1 million. The company achieved net income of $4.8 million ($0.10 per share) and adjusted EBITDA of $44.1 million. Notable developments include a favorable EXPAREL patent litigation settlement extending exclusivity to 2039, elimination of EXPAREL royalty obligations to RDF, and headquarters relocation to Brisbane, California. The company maintains its 2025 guidance with total revenue projected at $725-765 million. Pacira also completed the strategic acquisition of GQ Bio and initiated a Phase 2 study for PCRX-201 in knee osteoarthritis treatment. The company announced a $300 million stock buyback program, demonstrating confidence in its long-term growth outlook.

Pacira BioSciences (NASDAQ: PCRX) announced it will present new 3-year data from its ongoing Phase 1 study of PCRX-201 (enekinragene inzadenovec) at the 2025 EULAR Annual Congress in Barcelona. The presentation will focus on safety and efficacy data of this gene therapy candidate following a single intra-articular injection for moderate-to-severe knee osteoarthritis. The presentation titled "A Single Intra-articular Injection of the Gene Therapy PCRX-201 Was Safe and Provided Sustained Clinical Benefits for Patients With Moderate-to-Severe Knee Osteoarthritis Through 3 Years" will be delivered by Professor Philip G. Conaghan from the University of Leeds on June 11, 2025.

Pacira BioSciences (NASDAQ: PCRX) announced it will present findings from its Phase 1 study of PCRX-201, a gene therapy candidate for knee osteoarthritis, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) on May 15, 2025. The presentation will focus on how neutralizing antibodies (NAbs) affect the therapy's efficacy, safety, and potential for redosing.

Dr. MiJeong Kim, Senior Director of Translational Sciences, will deliver the presentation titled "Understanding the Clinical Immunogenicity of Locally Injected HCAd Vector Provides Insight into Optimizing Dosing Strategy." Additionally, Pacira will host a symposium on High-Capacity Adenoviral Vectors (HCAd) for common diseases, featuring speakers from Baylor College of Medicine and Pacira's development team.

Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after U.S. markets close.

Key details:

• Conference Call Time: 4:30 p.m. ET
• Participation Options: Live conference call and webcast
• Access Method: Pre-registration required for Q&A telephone participation
• Alternative Access: Live audio webcast available through "Events" page on investor.pacira.com
• Replay Availability: Webcast recording accessible for approximately two weeks post-call

Pacira BioSciences (Nasdaq: PCRX) has announced promising two-year efficacy data for its gene therapy candidate PCRX-201 in treating knee osteoarthritis. The study, presented at the 2025 OARSI World Congress, demonstrated sustained improvements in knee pain, stiffness, and function across all severity levels following a single injection.

The Phase 1 trial involved 72 patients aged 30-80, with two cohorts receiving different treatment protocols. The corticosteroid-pretreated cohort showed superior results with 48-65% pain reduction and 53-72% stiffness reduction, compared to 41-58% pain and 33-53% stiffness reductions in the non-pretreated group.

No serious treatment-related adverse events were reported. The most common side effect was joint swelling, occurring in 36% of pretreated patients versus 61% of non-pretreated patients. PCRX-201 received FDA's RMAT designation in March 2024 and EMA's ATMP designation in May 2023. A Phase 2 study (ASCEND) is currently underway.